KRAS has mutations in a variety of cancers, among which the mutation rate of pancreatic cancer is as high as 90%, that of colon cancer and lung cancer (mostly non-small cell lung cancer) account for 30–50% and 19% respectively, and cholangiocarcinoma accounts for about 26%. Here, KRAS is linked to cancer.